Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

The BVGH team will be presenting and representing WIPO Re:Search at several upcoming conferences.

Ujwal and Cathy will be attending the 65th Annual ASTMH Meeting in Atlanta. ASTMH presents an opportunity for our team to connect with Members from across the globe. If you or colleagues are heading to Atlanta, please reach out to Ujwal or Cathy to schedule a meeting.

Katy and I will both be presenting at the Eighth European & Developing Countries Clinical Trials Partnership (EDCTP) Forum in Lusaka, Zambia. We look forward to connecting with many of our African Members during the EDCTP Forum. Following EDCTP, Katy will be heading to South Africa to attend H3D: Malaria, Tuberculosis, and Neglected Tropical Diseases: Progress in Drug Discovery and Development in Cape Town. I will be giving a keynote address during the 1st Annual Tech Transfer Summit (TTS) Latin America Meeting in Medellin, Colombia.

WIPO will be hosting a WIPO Re:Search information session following the 28th IFPMA Assembly on November 30th. If you will be attending the Assembly or in Washington DC on the 30th, please join us to learn about the first five years of WIPO Re:Search and meet the WIPO Re:Search Advisory Committee members.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
**Special Announcement**

WIPO invites all interested parties to attend an information session on WIPO Re:Search and meet the WIPO Re:Search Advisory Committee members. The meeting will be held on **Wednesday, November 30th, 2pm – 3pm** at the Ritz-Carlton Pentagon City. Click [here](#) to learn more.

**WIPO Re:Search Statistics**

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

---

**WIPO Re:Search Kinetoplastid Collaborations**

<table>
<thead>
<tr>
<th></th>
<th>Drugs</th>
<th>Diagnostics</th>
<th>Vaccines</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14</td>
<td>2</td>
<td>1</td>
<td>17</td>
</tr>
</tbody>
</table>

**Participating WIPO Re:Search Members:**

- Center for Infectious Disease Research
- Drugs for Neglected Diseases Initiative
- Eisai
- Fundacao Oswaldo Cruz
- GlaxoSmithKline
- Institut Pasteur Korea
- McGill University
- National Institutes of Health
- Northeastern University
- Stanford University
- Swiss Tropical and Public Health Institute
- University of British Columbia
- University of California, San Diego
- University of California, San Francisco
- University of Dundee
- University of Washington
Cornerstones of Collaboration

Dr. Dylan Pillai, Associate Professor, University of Calgary, and colleagues at PATH recently published the results of their WIPO Re:Search collaboration. Through this collaboration, Dylan’s lab evaluated the efficacy of PATH’s non-instrumented nucleic acid amplification (NINA) heater coupled with a loop-mediated isothermal amplification (LAMP) assay to detect traveler’s malaria. Click here to read the paper. This is the second publication to result from Dylan and PATH’s collaboration. Click here to read their other paper.

Partnership Hub Central

WIPO hosted a Member meeting to obtain feedback and input on the WIPO Re:Search medium-term five-year strategic plan (MTSP). Click here to download the summary of the Member meeting.

Dr. Katy Graef presented WIPO Re:Search during a panel session at the 2016 Global Humanitarian Technology Conference in Seattle.

BVGH FundFinder Featured Funding Announcement

**Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis Disease (RFA-AI-16-079)**

The purpose of this award is to solicit research applications for milestone-driven projects focused on establishing proof-of-concept for and/or preclinical development of lead candidate vaccines targeting infection with *Mycobacterium tuberculosis* (Mt) and/or tuberculosis disease (TB).

**Proof-of-concept:** Projects must initiate with favorable candidates with demonstrated capacity to elicit an immune response in a relevant animal model for Mtb infection and/or TB. Approaches to demonstrate proof-of-concept and evaluate candidate vaccines under a variety of informative experimental conditions are encouraged. Relevant aspects of the immune response should be investigated in the most appropriate models to gain further insight into the biological complexity underlying vaccine-induced immunity. The completion of proof-of-concept activities is expected to result in the selection of a lead candidate vaccine or related product deemed appropriate for subsequent preclinical product development.

**Preclinical development:** Proposed activities should focus on advancement of the lead candidate vaccine toward licensure. Applications that would significantly advance a candidate vaccine toward clinical usefulness are responsive and highly encouraged; however, projects are not required to result in a “final” product, nor is it necessary to propose completion of the product development process up to the point of readiness for clinical trials or validation within the
time frame of the project.

**Funding amount:** $750,000 per year for up to 5 years  
**Funder:** National Institutes of Health (NIH)  
**Deadline:** Letter of intent due Feb. 2, 2017  
**Eligibility:** Open to academic, nonprofit, for-profit, and government entities based in the US and abroad

For more information about BVGH FundFinder, please email Lisel Koepl.

---

**Highlighted Contributions**

Featured this month a contribution submitted by Drugs for Neglected Diseases initiative (DNDi) to the WIPO Re:Search Database.

**Novel Leishmania donovani screening cascade (ID: 3101)**  
A novel axenic amastigote *Leishmania* assay was developed and validated that reports only cytocidal molecules. It was used to screen a diversity-oriented synthesis library. The library is a set of structurally diverse small molecules that combine the complexity of natural products and the efficiency of high-throughput synthesis, with a higher ratio of sp3-hybridized atoms and stereocenters relative to compounds found in conventional screens. Two new chemical series with antileishmanial activity were identified via this novel screening assay. The new axenic assay has a significantly improved translation to an intracellular assay. Click here to learn more about this new assay.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.

---

**WIPO Re:Search in the News**

WIPO launched a new global program to boost access of inventors and small enterprises in developing countries to the patent system. The Inventor Assistance Program provides developing world inventors with the pro bono help of patent attorneys.

---

**Upcoming Global Health Meetings**

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan. 14-18</td>
<td>Keystone Symposium: New Developments in Our Basic Understanding of Tuberculosis</td>
<td>Vancouver, Canada</td>
<td>Website</td>
</tr>
<tr>
<td>Feb. 19-22</td>
<td>Keystone Symposium: Malaria: From Innovation to Eradication</td>
<td>Kampala, Uganda</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 12-17</td>
<td>Gordon Research Conference: Tropical Infectious Diseases</td>
<td>Galveston, TX</td>
<td>Website</td>
</tr>
</tbody>
</table>